Cookies used for improved website experience

Siemens Healthineers and our partners use cookies and other similar technologies to operate the Siemens Healthineers websites and personalize content and ads. You may find out more about how we use cookies by clicking "Show details" or by referring to our Cookie Policy.
You may allow all cookies or select them individually. And you may change your consent and cookie preferences anytime by clicking on the "Review and change your consent" button on the Cookie Policy page.

SARS-CoV-2 Total Assay*: Securing your Community with Science and Scale

Jim Freeman
Vice President, Research and Development, Global Immunoassay Development
Siemens Healthineers | May 11, 2020

The COVID-19 pandemic has profoundly disrupted the world. Tools that can help address the full spectrum of challenges to help secure communities and combat this pandemic are needed. Testing large numbers of individuals for immune response/antibody status against the SARS-CoV-2 virus may help with re-opening society and assessing vaccine response (once available), as well as for managing the potential threat of additional infections.

In this video Jim Freeman discusses how design matters for SARS-CoV-2 antibody assays, especially the smart selection of the S1RBD antigen to detect antibodies that may block the virus entry into cells and how this strategy is aligned with vaccines in development.